C, W135and Y are available and used according to the recommendations of the standing committee (STIKO). Since 2013 a new recombinant 4-component meningococcus B vaccine (4CMenB) has been approved. The strain
while class I Pilin E induces highly specific antibodies (Abs) and class II induces cross-reacting Abs. Furthermore, complement cascade activation, as well as particularly C3b activation, opsonizes antigens, thereby enabling